文献速递睡眠呼吸障碍呼吸危重症与机械通气

CPAP与无创通气初始治疗肥胖低通气综合征的随机对照试验

A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome.
PubMed 文献 · Thorax · 2016-11-15

这项多中心、平行、双盲随机对照试验比较了双水平气道正压(Bi-level PAP)与持续气道正压(CPAP)对严重肥胖低通气综合征(OHS)的初始治疗效果。60例患者随机分组,57例完成3个月随访分析,两组治疗失败率、依从性、清醒PaCO2、嗜睡及健康相关生活质量改善均无显著差异,基线PaCO2是持续通气衰竭的唯一显著预测因素。

要点

  • Bi-level PAP与CPAP治疗严重OHS的3个月治疗失败率无显著差异。
  • 两组依从性、清醒PaCO2、嗜睡及生活质量改善均相似。
  • 基线PaCO2是持续通气衰竭的显著预测因素。

核心结论

  • 在新诊断的严重OHS中,Bi-level PAP与CPAP在通气衰竭、健康相关生活质量和依从性方面改善相似。
  • 基线PaCO2可预测治疗中持续通气衰竭。

研究设计与样本

  • 多中心、平行、双盲随机对照试验,比较夜间Bi-level PAP与CPAP初始治疗3个月。
  • 60例随机,57例完成随访并纳入分析;平均年龄53岁,BMI 55 kg/m2,PaCO2 60 mm Hg。

主要发现

  • 治疗失败率:Bi-level PAP组14.8% vs CPAP组13.3%,p=0.87。
  • 3个月依从性:Bi-level PAP组5.3小时/晚 vs CPAP组5.0小时/晚,p=0.62。
  • 3个月清醒PaCO2:Bi-level PAP组44.2 mm Hg vs CPAP组45.9 mm Hg,p=0.60。
  • 嗜睡改善组间差异:Epworth嗜睡量表0.3(95%CI -2.8, 3.4),p=0.86。
  • 健康相关生活质量改善组间差异:SF36-SF6d 0.025(95%CI -0.039, 0.088),p=0.45。

临床怎么用

  • 对于新诊断的严重OHS,CPAP与Bi-level PAP均可作为初始治疗选择,两者在3个月内的疗效与依从性相似。
  • 基线PaCO2较高的患者应警惕持续通气衰竭风险,需加强随访监测。

局限性

  • 样本量较小(60例随机,57例分析)。
  • 随访时间仅3个月,长期成本效果及对死亡率的影响尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity hypoventilation syndrome (OHS) is the most common indication for home ventilation, although the optimal therapy remains unclear, particularly for severe disease. We compared Bi-level and continuous positive airways pressure (Bi-level positive airway pressure (PAP); CPAP) for treatment of severe OHS. METHODS: We conducted a multicentre, parallel, double-blind trial for initial treatment of OHS, with participants randomised to nocturnal Bi-level PAP or CPAP for 3 months. The primary outcome was frequency of treatment failure (hospital admission, persistent ventilatory failure or non-adherence); secondary outcomes included health-related quality of life (HRQoL) and sleepiness. RESULTS: Sixty participants were randomised; 57 completed follow-up and were included in analysis (mean age 53 years, body mass index 55 kg/m2, PaCO2 60 mm Hg). There was no difference in treatment failure between groups (Bi-level PAP, 14.8% vs CPAP, 13.3%, p=0.87). Treatment adherence and wake PaCO2 were similar after 3 months (5.3 hours/night Bi-level PAP, 5.0 hours/night CPAP, p=0.62; PaCO2 44.2 and 45.9 mm Hg, respectively, p=0.60). Between-group differences in improvement in sleepiness (Epworth Sleepiness Scale 0.3 (95% CI -2.8, 3.4), p=0.86) and HRQoL (Short Form (SF)36-SF6d 0.025 (95% CI -0.039, 0.088), p=0.45) were not significant. Baseline severity of ventilatory failure (PaCO2) was the only significant predictor of persistent ventilatory failure at 3 months (OR 2.3, p=0.03). CONCLUSIONS: In newly diagnosed severe OHS, Bi-level PAP and CPAP resulted in similar improvements in ventilatory failure, HRQoL and adherence. Baseline PaCO2 predicted persistent ventilatory failure on treatment. Long-term studies are required to determine whether these treatments have different cost-effectiveness or impact on mortality. TRIAL REGISTRATION NUMBER: ACTRN12611000874910, results.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Howard ME, Piper AJ, Stevens B, et al. A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome. Thorax. 2016. PMID: 27852952. doi:10.1136/thoraxjnl-2016-208559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。